Secondaries announced 9.21.2016
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Sarepta Therapeutics, Inc. Symbol: SRPT Price: Last trade $56.09 Trade Date: 9/23 Shares: 4 million Underwriter(s) J.P. Morgan, Goldman Sachs, Credit[…]